# Dxcover

Source: https://onco.cc/companies/dxcover/  
OnCo record `dxcover` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Glasgow company whose infrared blood test is sold in the UK for brain tumours and is being studied for several other cancers.

## Summary

Dxcover Limited, of Glasgow with a US entity in Tennessee, led by co-founder Matthew Baker, develops Fourier transform infrared spectroscopy of serum. Its brain tumour test is UKCA-marked and the company announced CE-IVDR Class C certification in March 2026; the multi-cancer application is in study.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Glasgow
- Type: diagnostics
- Website: https://www.dxcover.com/

## Sources

- Official website: https://www.dxcover.com/

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Dxcover Cancer Liquid Biopsy](https://onco.cc/drugs/dxcover-cancer-liquid-biopsy/)
- key papers: [A spectroscopic liquid biopsy for the earlier detection of multiple cancer types](https://onco.cc/key-papers/paper-dxcover-spectroscopy-bjc-2023/)

---
JSON: https://onco.cc/api/v1/entities/dxcover.json